Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis

Li Li, Yingzi Luan, Xiping Li, Bujian Tang, Wei Zhang, Danrong Li, Jinshun Zhao, Gangduo Wang, Hong Ding, Eddie Reed, Qingdi Q. Li

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Chemotherapy plays a major role in cancer management; however, acquired drug resistance remains a significant problem for ovarian cancer treatment. Chemoresistance is regulated by the coordinated expression of a set of genes. Thus, the identification of genes specifically modulated in the process provides an important step toward the discovery of underlying molecular mechanisms in drug resistance events. We recently developed five drug-resistant human ovarian carcinoma cell lines, including two cisplatin (cis) resistant cell lines, two carboplatin (car) resistant cell lines and one taxol (tax) resistant cell line. In this study, we investigated differential gene expression between these resistant cell lines and their parental cell lines by the fluorescence differential display-polymerase chain reaction (FDD-PCR) technique. We first screened and identified differentially expressed genes in the resistant ovarian cancer cell lines, and we then sequenced and analyzed these genes by bioinformatics software. A total of 33 fragments were displayed in the two resistant cell lines (S-cis and S-car) derived from the sensitive SKOV-3 cell line, and 36 fragments were displayed in the three resistant cell lines (A-cis, A-car and A-tax) derived from the sensitive A2780 cell line. After purification, cloning, sequencing, and homology analysis on the NCBI BLAST GenBank, 12 gene fragments were identified from the resistant S-cis and S-car cells, and 23 gene fragments were identified from the resistant A-cis, A-car and A-tax cells. Although a homolog search of the NIH GenBank revealed that most of the gene fragments were not significantly associated with the known drug resistance-related genes, our study conclusively demonstrates that FDD-PCR is a useful tool for analyzing the differential gene expression between resistant and sensitive tumor cells and for identifying novel chemoresistance-associated genes and potential biological markers or genetic markers of drug resistance.

Original languageEnglish (US)
Pages (from-to)793-799
Number of pages7
JournalOncology Reports
Volume13
Issue number5
StatePublished - May 2005
Externally publishedYes

Fingerprint

Fluorescence
Gene Expression
Cell Line
Polymerase Chain Reaction
Carboplatin
Neoplasms
Cisplatin
Genes
Drug Resistance
Paclitaxel
Nucleic Acid Databases
Ovarian Neoplasms
Computational Biology
Genetic Markers
Organism Cloning
Software
Biomarkers
Carcinoma
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Carboplatin
  • Cisplatin
  • Differential gene expression
  • Drug resistance
  • Fluorescence differential display-polymerase chain reaction
  • Ovarian cancer
  • Paclitaxel
  • Taxol

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis. / Li, Li; Luan, Yingzi; Li, Xiping; Tang, Bujian; Zhang, Wei; Li, Danrong; Zhao, Jinshun; Wang, Gangduo; Ding, Hong; Reed, Eddie; Li, Qingdi Q.

In: Oncology Reports, Vol. 13, No. 5, 05.2005, p. 793-799.

Research output: Contribution to journalArticle

Li, L, Luan, Y, Li, X, Tang, B, Zhang, W, Li, D, Zhao, J, Wang, G, Ding, H, Reed, E & Li, QQ 2005, 'Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis', Oncology Reports, vol. 13, no. 5, pp. 793-799.
Li, Li ; Luan, Yingzi ; Li, Xiping ; Tang, Bujian ; Zhang, Wei ; Li, Danrong ; Zhao, Jinshun ; Wang, Gangduo ; Ding, Hong ; Reed, Eddie ; Li, Qingdi Q. / Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis. In: Oncology Reports. 2005 ; Vol. 13, No. 5. pp. 793-799.
@article{dd7f9d692c57410c933327bac66c02cc,
title = "Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis",
abstract = "Chemotherapy plays a major role in cancer management; however, acquired drug resistance remains a significant problem for ovarian cancer treatment. Chemoresistance is regulated by the coordinated expression of a set of genes. Thus, the identification of genes specifically modulated in the process provides an important step toward the discovery of underlying molecular mechanisms in drug resistance events. We recently developed five drug-resistant human ovarian carcinoma cell lines, including two cisplatin (cis) resistant cell lines, two carboplatin (car) resistant cell lines and one taxol (tax) resistant cell line. In this study, we investigated differential gene expression between these resistant cell lines and their parental cell lines by the fluorescence differential display-polymerase chain reaction (FDD-PCR) technique. We first screened and identified differentially expressed genes in the resistant ovarian cancer cell lines, and we then sequenced and analyzed these genes by bioinformatics software. A total of 33 fragments were displayed in the two resistant cell lines (S-cis and S-car) derived from the sensitive SKOV-3 cell line, and 36 fragments were displayed in the three resistant cell lines (A-cis, A-car and A-tax) derived from the sensitive A2780 cell line. After purification, cloning, sequencing, and homology analysis on the NCBI BLAST GenBank, 12 gene fragments were identified from the resistant S-cis and S-car cells, and 23 gene fragments were identified from the resistant A-cis, A-car and A-tax cells. Although a homolog search of the NIH GenBank revealed that most of the gene fragments were not significantly associated with the known drug resistance-related genes, our study conclusively demonstrates that FDD-PCR is a useful tool for analyzing the differential gene expression between resistant and sensitive tumor cells and for identifying novel chemoresistance-associated genes and potential biological markers or genetic markers of drug resistance.",
keywords = "Carboplatin, Cisplatin, Differential gene expression, Drug resistance, Fluorescence differential display-polymerase chain reaction, Ovarian cancer, Paclitaxel, Taxol",
author = "Li Li and Yingzi Luan and Xiping Li and Bujian Tang and Wei Zhang and Danrong Li and Jinshun Zhao and Gangduo Wang and Hong Ding and Eddie Reed and Li, {Qingdi Q.}",
year = "2005",
month = "5",
language = "English (US)",
volume = "13",
pages = "793--799",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis

AU - Li, Li

AU - Luan, Yingzi

AU - Li, Xiping

AU - Tang, Bujian

AU - Zhang, Wei

AU - Li, Danrong

AU - Zhao, Jinshun

AU - Wang, Gangduo

AU - Ding, Hong

AU - Reed, Eddie

AU - Li, Qingdi Q.

PY - 2005/5

Y1 - 2005/5

N2 - Chemotherapy plays a major role in cancer management; however, acquired drug resistance remains a significant problem for ovarian cancer treatment. Chemoresistance is regulated by the coordinated expression of a set of genes. Thus, the identification of genes specifically modulated in the process provides an important step toward the discovery of underlying molecular mechanisms in drug resistance events. We recently developed five drug-resistant human ovarian carcinoma cell lines, including two cisplatin (cis) resistant cell lines, two carboplatin (car) resistant cell lines and one taxol (tax) resistant cell line. In this study, we investigated differential gene expression between these resistant cell lines and their parental cell lines by the fluorescence differential display-polymerase chain reaction (FDD-PCR) technique. We first screened and identified differentially expressed genes in the resistant ovarian cancer cell lines, and we then sequenced and analyzed these genes by bioinformatics software. A total of 33 fragments were displayed in the two resistant cell lines (S-cis and S-car) derived from the sensitive SKOV-3 cell line, and 36 fragments were displayed in the three resistant cell lines (A-cis, A-car and A-tax) derived from the sensitive A2780 cell line. After purification, cloning, sequencing, and homology analysis on the NCBI BLAST GenBank, 12 gene fragments were identified from the resistant S-cis and S-car cells, and 23 gene fragments were identified from the resistant A-cis, A-car and A-tax cells. Although a homolog search of the NIH GenBank revealed that most of the gene fragments were not significantly associated with the known drug resistance-related genes, our study conclusively demonstrates that FDD-PCR is a useful tool for analyzing the differential gene expression between resistant and sensitive tumor cells and for identifying novel chemoresistance-associated genes and potential biological markers or genetic markers of drug resistance.

AB - Chemotherapy plays a major role in cancer management; however, acquired drug resistance remains a significant problem for ovarian cancer treatment. Chemoresistance is regulated by the coordinated expression of a set of genes. Thus, the identification of genes specifically modulated in the process provides an important step toward the discovery of underlying molecular mechanisms in drug resistance events. We recently developed five drug-resistant human ovarian carcinoma cell lines, including two cisplatin (cis) resistant cell lines, two carboplatin (car) resistant cell lines and one taxol (tax) resistant cell line. In this study, we investigated differential gene expression between these resistant cell lines and their parental cell lines by the fluorescence differential display-polymerase chain reaction (FDD-PCR) technique. We first screened and identified differentially expressed genes in the resistant ovarian cancer cell lines, and we then sequenced and analyzed these genes by bioinformatics software. A total of 33 fragments were displayed in the two resistant cell lines (S-cis and S-car) derived from the sensitive SKOV-3 cell line, and 36 fragments were displayed in the three resistant cell lines (A-cis, A-car and A-tax) derived from the sensitive A2780 cell line. After purification, cloning, sequencing, and homology analysis on the NCBI BLAST GenBank, 12 gene fragments were identified from the resistant S-cis and S-car cells, and 23 gene fragments were identified from the resistant A-cis, A-car and A-tax cells. Although a homolog search of the NIH GenBank revealed that most of the gene fragments were not significantly associated with the known drug resistance-related genes, our study conclusively demonstrates that FDD-PCR is a useful tool for analyzing the differential gene expression between resistant and sensitive tumor cells and for identifying novel chemoresistance-associated genes and potential biological markers or genetic markers of drug resistance.

KW - Carboplatin

KW - Cisplatin

KW - Differential gene expression

KW - Drug resistance

KW - Fluorescence differential display-polymerase chain reaction

KW - Ovarian cancer

KW - Paclitaxel

KW - Taxol

UR - http://www.scopus.com/inward/record.url?scp=25144514578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144514578&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 793

EP - 799

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -